GoodRx (NASDAQ:GDRX) Shares Gap Up - What's Next?

Key Points

• GoodRx shares saw a significant price increase, gapping up from a previous close of $3.73 to an opening price of $4.65, and last traded at $5.03 with substantial trading volume.
• Wall Street analysts have adjusted their price targets for GoodRx, with Goldman Sachs lowering theirs from $6.00 to $5.00, indicating a cautious outlook with a "neutral" rating.
• The company's latest earnings report revealed a miss in EPS expectations, posting $0.09 against the $0.10 consensus, and a slight 1.2% increase in quarterly revenue compared to the previous year.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $3.73, but opened at $4.65. GoodRx shares last traded at $5.03, with a volume of 10,672,040 shares.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GDRX shares. The Goldman Sachs Group decreased their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. UBS Group decreased their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Wells Fargo & Company decreased their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Finally, Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.80.

GoodRx Trading Up 37.4%

The stock has a market cap of $1.78 billion, a price-to-earnings ratio of 50.65, a P/E/G ratio of 1.53 and a beta of 1.24. The business's fifty day simple moving average is $4.56 and its 200 day simple moving average is $4.51. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 earnings per share. On average, research analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.17% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citizens Financial Group Inc. RI bought a new stake in GoodRx in the first quarter worth about $44,000. Jump Financial LLC bought a new stake in GoodRx in the first quarter worth about $49,000. Cetera Investment Advisers bought a new stake in GoodRx in the second quarter worth about $50,000. Walled Lake Planning & Wealth Management LLC bought a new stake in GoodRx in the second quarter worth about $55,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in GoodRx in the fourth quarter worth about $56,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.